Position in NDRA
as of Jun 30, 2026
· filed Sep 2, 2026
Position Value
$159,494
+$108,113 QoQ
Shares Held
29,924
+142395.2% QoQ
Ownership
2.00%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#2
of 10 holders
Holding Since
Jun 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NDRA Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $1,695,016,013 across 33 Diagnostics & Research names. NDRA ranks #29 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
574,992 | $288,277,988 | |
| 2 | CRL |
Charles River Laboratories International, Inc.
|
1,193,601 | $270,696,770 | |
| 3 | GH |
Guardant Health, Inc.
|
1,449,534 | $217,473,585 | |
| 4 | DHR |
Danaher Corp /De/
|
943,694 | $179,754,833 | |
| 5 | RVTY |
Revvity, Inc.
|
1,457,335 | $162,143,091 | |
| 6 | A |
Agilent Technologies, Inc.
|
1,101,501 | $146,312,377 | |
| 7 | NTRA |
Natera, Inc.
|
265,607 | $72,099,020 | |
| 8 | WGS |
GeneDx Holdings Corp.
|
865,462 | $59,413,965 |
All Filings in NDRA
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $159,494 | 29,924 | Shares | Defined | 2026-09-02 | |
| 2023-06-30 | $51,381 | 36,701 | Shares | Defined | 2023-08-14 | |
| 2022-09-30 | $23,242 | 75,957 | Shares | Defined | 2022-11-14 | |
| 2021-12-31 | $34,259 | 49,508 | Shares | Defined | 2022-02-14 | |
| 2021-09-30 | $26,406 | 15,264 | Shares | Defined | 2021-11-15 | |
| 2021-03-31 | $129,625 | 49,856 | Shares | Defined | 2021-05-21 | |
| 2020-09-30 | $32,896 | 44,941 | Shares | Defined | 2020-11-16 | |
| 2020-06-30 | $35,564 | 36,969 | Shares | Defined | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||